Cargando…
A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3
With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations,...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/ https://www.ncbi.nlm.nih.gov/pubmed/35455739 http://dx.doi.org/10.3390/jpm12040623 |
_version_ | 1784690907739586560 |
---|---|
author | de la Fouchardière, Christelle Gamradt, Pia Chabaud, Sylvie Raddaz, Maxime Blanc, Ellen Msika, Olivier Treilleux, Isabelle Bachy, Sophie Cattey-Javouhey, Anne Guibert, Pierre Sarabi, Matthieu Rochefort, Pauline Funk-Debleds, Pamela Coutzac, Clélia Ray-Coquard, Isabelle Peyrat, Patrice Meeus, Pierre Rivoire, Michel Dupré, Aurélien Hennino, Ana |
author_facet | de la Fouchardière, Christelle Gamradt, Pia Chabaud, Sylvie Raddaz, Maxime Blanc, Ellen Msika, Olivier Treilleux, Isabelle Bachy, Sophie Cattey-Javouhey, Anne Guibert, Pierre Sarabi, Matthieu Rochefort, Pauline Funk-Debleds, Pamela Coutzac, Clélia Ray-Coquard, Isabelle Peyrat, Patrice Meeus, Pierre Rivoire, Michel Dupré, Aurélien Hennino, Ana |
author_sort | de la Fouchardière, Christelle |
collection | PubMed |
description | With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations, PDAC has not yet benefited from the recent therapeutic advances that immune checkpoint inhibitors (ICI) have provided in other cancer types, except in specific subgroups of patients presenting with tumors with high mutational burden (TMB) or microsatellite instability (MSI). The tumor microenvironment (TME) plays a substantial role in therapeutic resistance by facilitating immune evasion. An extracellular stromal protein, βig-h3/TGFβi, is involved in the pathogenesis of PDAC by hampering T cell activation and promoting stiffness of the TME. The study BIGHPANC included 41 patients with metastatic PDAC, and analyzed βig-h3 levels in serum and tumor samples to assess the βig-h3 prognostic value. βig-h3 serum levels are significantly associated with overall survival (HR 2.05, 95%CI 1.07–3.93; p = 0.0301). Our results suggest that βig-h3 serum levels may be considered a prognostic biomarker in patients with metastatic PDAC. |
format | Online Article Text |
id | pubmed-9025577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90255772022-04-23 A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 de la Fouchardière, Christelle Gamradt, Pia Chabaud, Sylvie Raddaz, Maxime Blanc, Ellen Msika, Olivier Treilleux, Isabelle Bachy, Sophie Cattey-Javouhey, Anne Guibert, Pierre Sarabi, Matthieu Rochefort, Pauline Funk-Debleds, Pamela Coutzac, Clélia Ray-Coquard, Isabelle Peyrat, Patrice Meeus, Pierre Rivoire, Michel Dupré, Aurélien Hennino, Ana J Pers Med Article With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations, PDAC has not yet benefited from the recent therapeutic advances that immune checkpoint inhibitors (ICI) have provided in other cancer types, except in specific subgroups of patients presenting with tumors with high mutational burden (TMB) or microsatellite instability (MSI). The tumor microenvironment (TME) plays a substantial role in therapeutic resistance by facilitating immune evasion. An extracellular stromal protein, βig-h3/TGFβi, is involved in the pathogenesis of PDAC by hampering T cell activation and promoting stiffness of the TME. The study BIGHPANC included 41 patients with metastatic PDAC, and analyzed βig-h3 levels in serum and tumor samples to assess the βig-h3 prognostic value. βig-h3 serum levels are significantly associated with overall survival (HR 2.05, 95%CI 1.07–3.93; p = 0.0301). Our results suggest that βig-h3 serum levels may be considered a prognostic biomarker in patients with metastatic PDAC. MDPI 2022-04-12 /pmc/articles/PMC9025577/ /pubmed/35455739 http://dx.doi.org/10.3390/jpm12040623 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article de la Fouchardière, Christelle Gamradt, Pia Chabaud, Sylvie Raddaz, Maxime Blanc, Ellen Msika, Olivier Treilleux, Isabelle Bachy, Sophie Cattey-Javouhey, Anne Guibert, Pierre Sarabi, Matthieu Rochefort, Pauline Funk-Debleds, Pamela Coutzac, Clélia Ray-Coquard, Isabelle Peyrat, Patrice Meeus, Pierre Rivoire, Michel Dupré, Aurélien Hennino, Ana A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 |
title | A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 |
title_full | A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 |
title_fullStr | A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 |
title_full_unstemmed | A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 |
title_short | A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3 |
title_sort | promising biomarker and therapeutic target in patients with advanced pdac: the stromal protein βig-h3 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025577/ https://www.ncbi.nlm.nih.gov/pubmed/35455739 http://dx.doi.org/10.3390/jpm12040623 |
work_keys_str_mv | AT delafouchardierechristelle apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT gamradtpia apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT chabaudsylvie apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT raddazmaxime apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT blancellen apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT msikaolivier apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT treilleuxisabelle apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT bachysophie apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT catteyjavouheyanne apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT guibertpierre apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT sarabimatthieu apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT rochefortpauline apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT funkdebledspamela apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT coutzacclelia apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT raycoquardisabelle apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT peyratpatrice apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT meeuspierre apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT rivoiremichel apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT dupreaurelien apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT henninoana apromisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT delafouchardierechristelle promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT gamradtpia promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT chabaudsylvie promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT raddazmaxime promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT blancellen promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT msikaolivier promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT treilleuxisabelle promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT bachysophie promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT catteyjavouheyanne promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT guibertpierre promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT sarabimatthieu promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT rochefortpauline promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT funkdebledspamela promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT coutzacclelia promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT raycoquardisabelle promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT peyratpatrice promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT meeuspierre promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT rivoiremichel promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT dupreaurelien promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 AT henninoana promisingbiomarkerandtherapeutictargetinpatientswithadvancedpdacthestromalproteinbigh3 |